Repligen (NASDAQ:RGEN) Price Target Raised to $225.00

Repligen (NASDAQ:RGEN) had its price target boosted by UBS Group from $195.00 to $225.00 in a research report sent to investors on Wednesday morning, Marketbeat.com reports. They currently have a buy rating on the biotechnology company’s stock.

RGEN has been the subject of a number of other reports. Citigroup upgraded shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective on the stock. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 13th. Wells Fargo & Company lifted their target price on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, Evercore reiterated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $168.57.

Repligen Stock Performance

NASDAQ RGEN opened at $165.18 on Wednesday. The stock has a market cap of $9.32 billion, a PE ratio of 226.27, a P/E/G ratio of 3.01 and a beta of 1.05. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $100.99 and a twelve month high of $188.73. The stock has a fifty day simple moving average of $158.22 and a 200-day simple moving average of $135.29.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period in the previous year, the firm earned $0.26 EPS. Repligen’s revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts anticipate that Repligen will post 2.06 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, CFO Jason Garland sold 733 shares of Repligen stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares of the company’s stock, valued at $2,807,055. The trade was a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its stake in Repligen by 13,158.5% during the 2nd quarter. California State Teachers Retirement System now owns 8,201,681 shares of the biotechnology company’s stock worth $1,119,037,000 after buying an additional 8,139,821 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares in the last quarter. United Capital Financial Advisors LLC purchased a new position in Repligen in the 2nd quarter valued at approximately $380,756,000. Opti Capital Management LP purchased a new position in Repligen in the 4th quarter valued at approximately $2,399,209,000. Finally, Wasatch Advisors LP grew its stake in shares of Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock worth $216,974,000 after acquiring an additional 346,720 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to develop and produce biologic drugs. Its products are designed to support key stages of biomanufacturing, including upstream processing, downstream purification, filtration, and process monitoring.

The company’s portfolio includes chromatography products, filtration and single-use systems, process analytics technologies, and recombinant proteins such as Protein A-based products.